Last mentioned: Mar 17, 2026
New Limits Reported
States begin implementing restrictive eligibility and waitlists for drug assistance programs.
Fiscal Pressure Mounts
Rising costs of long-acting therapies and expiration of pandemic funding strain state budgets.
Waitlist Peak
National ADAP waitlists reached a record high of over 9,000 individuals following the Great Recession.
Ryan White CARE Act
Federal legislation established to provide a safety net for HIV/AIDS care and treatment.
Several states have begun implementing restrictive eligibility requirements and waitlists for AIDS Drug Assistance Programs (ADAPs), citing budgetary shortfalls and rising medication costs. This shift threatens to reverse years of progress in HIV viral suppression and places significant financial pressure on low-income patients and safety-net providers.
The Florida Legislature has approved a stopgap bill to restore essential funding to the state's AIDS Drug Assistance Program (ADAP), averting a potential crisis in medication access. This legislative action ensures that thousands of low-income residents living with HIV/AIDS will continue to receive life-saving antiretroviral treatments without interruption.
This page surfaces every story mentioning Gilead Sciences across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Gilead Sciences was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |